Nogawa Hideyuki, Horikoshi Hiroyuki, Oya Nariyuki, Akiyoshi Tsukasa
Department of Gastroenterology, Gunma Prefectural Cancer Center, Japan.
Gan To Kagaku Ryoho. 2011 Oct;38(10):1717-22.
Hepatic artery chemotherapy with transarterial infusion (TAI) of a cisplatin formulation designed for intra-arterial injection (IA-call®) is recognized as an established treatment for advanced hepatocellular carcinoma (HCC). We experienced three patients whose multiple HCC(Stage III) was successfully treated by TAI using IA-call combined with embolization by porous gelatin particles (Gelpart®), after a series of treatments such as hepatectomy, radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), and TAI. Cisplatin-based TAI was not effective, but porous gelatin particles showed a therapeutic effect in one patient by reducing his hepatic arterial blood flow. The two other patients responded to combination therapy after the second treatment. Adverse events from the treatment were mild. This therapy has benefits even for multiple intra-hepatic lesions that are resistant to TACE and TAI because of its widespread effect on the entire liver, and it could be an effective treatment option for advanced HCC.
经动脉灌注(TAI)专为动脉内注射设计的顺铂制剂(IA-call®)进行肝动脉化疗,被认为是晚期肝细胞癌(HCC)的既定治疗方法。我们有三名患有多发性HCC(III期)的患者,在接受了诸如肝切除术、射频消融(RFA)、经动脉化疗栓塞(TACE)和TAI等一系列治疗后,通过使用IA-call联合多孔明胶颗粒(Gelpart®)栓塞的TAI成功得到治疗。基于顺铂的TAI无效,但多孔明胶颗粒通过减少一名患者的肝动脉血流显示出治疗效果。另外两名患者在第二次治疗后对联合治疗有反应。治疗的不良事件较轻。这种疗法即使对于因对TACE和TAI耐药的多发性肝内病变也有好处,因为它对整个肝脏有广泛影响,并且可能是晚期HCC的有效治疗选择。